New hope for mesothelioma? drug targets CD30-Positive tumors

NCT ID NCT03007030

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests brentuximab vedotin (Adcetris) in 55 patients with CD30+ malignant mesothelioma that cannot be removed by surgery. The drug is an antibody-drug conjugate designed to seek out and attack cancer cells carrying the CD30 marker. The main goal is to see if the drug can control the disease—shrink tumors or keep them stable—with a target of at least 50% of patients benefiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin (Adcetris)
What this could lead to: If successful, this could offer a new treatment option for patients with CD30+ mesothelioma that cannot be surgically removed.
What could go wrong: This is a small, early-phase trial (55 patients) with no control group. The drug may not shrink tumors or improve survival, and side effects like nerve damage or infusion reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD30-POSITIVE NEOPLASTIC CELLS PRESENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD30-POSITIVE NEOPLASTIC CELLS PRESENT MALIGNANT MESOTHELIOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.